Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
Syntax Bio and Applied StemCell Announce Strategic Collaboration to Advance Stem Cell Innovation
The companies will generate data using Applied StemCell’s induced pluripotent stem cell technologies and Syntax Bio’s Cellgorithm™ platform to support application discovery and development
CHICAGO & MILPITAS, Calif. — Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Applied StemCell Corp. (ASC), a leader in induced pluripotent stem cell (iPSC) technology and genome engineering, announced a strategic collaboration to help unlock the next generation of regenerative medicine. The collaboration will focus on evaluating ASC’s iPSC and hypoimmune cell lines using Syntax Bio’s proprietary Cellgorithm™ platform to advance stem cell research and therapeutic application discovery and development. [Read more…]
RoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess Solutions
Partnership pairs Applied StemCell’s induced pluripotent stem cell technology with RoosterBio’s engineered media, reagents, and scalable bioprocess systems to accelerate development and manufacturing of advanced therapies
MILPITAS, Calif. and FREDERICK, Md., July 8, 2026 — Applied StemCell, Inc., a biotechnology company with deep expertise and intellectual property in induced pluripotent stem cell (iPSC) technology, and RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions, today announced a strategic partnership to develop and commercialize scalable iPSC-based bioprocess solutions. The collaboration combines Applied StemCell’s GMP-compatible iPSC technology with RoosterBio’s engineered media systems and scalable manufacturing expertise to provide advanced therapy developers with a unique bioprocess solution supporting research through clinical manufacturing. [Read more…]
RoosterBio and Qkine Partner to Deliver a Single-Source Platform of Cells, Media, and Growth Factors to U.S. Customers
Distribution agreement gives U.S. customers a single-vendor source for high-quality cells, bioprocess media, and recombinant growth factors—giving cell and exosome therapy developers a single, translation-friendly source for critical raw materialsÂ
FREDERICK, MD., July 7, 2026 — RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions for hMSCs, iPSCs, and exosome therapeutic developers, today announced a distribution agreement with Qkine Ltd., a Cambridge, UK–based manufacturer of high-purity, animal origin-free recombinant growth factors, cytokines, and complex bioactive proteins. Under the agreement, customers in the United States can now order Qkine’s full range of translation-friendly research use only (RUO) growth factors and cytokines directly from RoosterBio. [Read more…]
UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson’s Therapy
SHANGHAI, June 23, 2026 — UniXell Biotechnology Co., Ltd. (“UniXell”) has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for UX-DA003, its allogeneic induced pluripotent stem cell (iPSC)-derived therapy for Parkinson’s disease. Paired with the prior IND approval from China’s National Medical Products Administration (NMPA) on June 3, 2026, the candidate will undergo clinical development in both China and the United States concurrently, marking a landmark dual-country breakthrough for the company’s neurodegenerative disease pipeline. This milestone solidifies UniXell’s unique dual-pathway clinical strategy covering personalized autologous and scalable off-the-shelf allogeneic iPSC therapeutics.
- 1
- 2
- 3
- …
- 79
- Next Page »